Experimental Drugs Considered for New York Ebola Patient
By Robert Langreth - Oct 25, 2014
The team at Bellevue Hospital Center treating Craig Spencer for Ebola is considering any and all experimental drugs or other treatments that might help him, an adviser to New York Mayor Bill de Blasio said. Doctors treating Spencer will consider “literally any and all possible therapies that might be available,” including various experimental Ebola therapies or blood transfusions from survivors, Irwin Redlener, director of the National Center for Disaster Preparedness at Columbia University and special adviser to de Blasio, said yesterday in a telephone interview.
“All bets are off with this,” Redlener said. “If it is necessary to save his life, if it is available, it will be tried.” In terms of experimental therapies, “I don’t know whether anything has been started or not, although I am positive it has been under discussion.” In the meantime, the focus is on providing high-quality supportive care, he said.
Spencer, the first patient to be diagnosed with Ebola in New York, was in stable condition at an isolation unit at Bellevue, New York City Health Commissioner Mary Bassett said yesterday at a briefing. Spencer was rushed to the hospital Oct. 23 after coming down with 100.3 fever. Tests later confirmed the virus.
Treatment So Far
Spencer was talking on the phone yesterday with family and friends, Bassett said. His treatment so far includes supporting his electrolytes and fluid balance, and carefully monitoring his vital signs, another official said at the briefing. An emergency medicine doctor at Columbia University-New York Presbyterian Hospital, Spencer worked with Doctors Without Borders in Guinea treating Ebola patients. He returned Oct. 17 to New York.
“It is not likely” that Spencer will be transferred to another hospital with more experience treating Ebola patients, Redlener said. In addition to help from expert
great news; thx for sharing!
from captian future:
Jefferies: $EXAS Seatbelts On: Preliminary CMS Pricing = Bull Case Scenario; Hiking Target to $27 (from $20)
$EXAS JMP "Above all Expectations" - price target to $34 from $28 following CMS' decision on Cologuard's coverage and reimbursement
how is that set up to be done in Yhoo MB? Pls advice
from the Fly via Twiiter:
September 24, 201407:15 EDT
EXASExact Sciences checks show robust early adoption trends, says Jefferies
Jefferies says its analysis of Exact Sciences' enrollment database indicates robust early adoption of Cologuard. The firm has increased conviction in its 2015 test volume forecasts and keeps a Buy rating on the stock with a $20 price target.
Micron and ASE began talks on jointly building an IC packaging/testing plant in Xian, China in early 2014, looking to sign a pact by the end of August, the sources noted.
The negotiations between Micron and ASE appear to have hit a snag, said the sources, although Micron's plan to set up a packaging/testing firm in Xian remains unchanged.
As a result, Micron is looking for a new partner and has started talks with PTI, one of its current backend service partners. Micron also outsources memory backend services to Walton Advanced Engineering and ChipMOS Technologies.
ASE, which focuses on logic chips, ranked as the top supplier in the global IC backend service market with an 18.9% share in 2013. PTI, which focuses on memory chips, took the fifth position with a 5.1% share, according to Gartner.
EXAS- 2,712 Oct $21 calls were bought for $1.04 each, against open interest of 1,076 contracts. Yesterday, EXACT Sciences announced that Group Health Cooperative will be the first health plan in Wisconsin to offer Cologuard (colorectal cancer screening test).
$EXAS Jefferies on CMS pricing - complete note: With CMS expected to release a preliminary pricing determination for Cologuard (Medicare is ~45% of target market) over the coming days, we handicap our expectations ahead of the event and revisit the bridge to our
2015 test volume forecast. Based on our weighted probability assessment, we
expect an ASP outcome of $370 under a cross-walk approach, slightly ahead of
CMS preview. CMS is expected to post its preliminary payment determinations for CY15
CLFS test codes over the coming days, including a payment decision for Cologuard (gapfill
vs. cross-walk), supporting rationale, and the existing codes used to cross-walk. By
way of background, EXAS recommended cross-walking to codes 81275 (KRAS), 81315 (two
methylation markers), and 82274 (FIT) for a proposed payment level of $502. CMS will
accept public comments until early-October and post finalized decisions in November.
Payments will go into effect in CY15, but CMS is expected to retroactively cover tests
performed after the final NCD.
Our Take. Based on our weighted probability assessment, we expect an ASP outcome of
$370 under a cross-walk approach (see Chart 1 on page 2), slightly ahead of our feel for
consensus. We peg the odds of a more bullish $400-500 scenario at ~33% and a $500+
outcome at ~10%. Our model contemplates a $350 ASP; each $50 ASP increment would
have a ~$2 impact to our DCF-based price target. We note that a $350 ASP outcome from
CMS would likely still offer upside to our intermediate-term forecasts, given private payor
rates will likely be at a premium to Medicare.
2015 test volume assumptions appear rational. EXAS expects to have ~100 reps
detailing Cologuard to high-volume FIT/FOBT docs by year-end. Assuming only a 70%
patient compliance rate (mgmt.'s bonus trigger), our 2015 volume forecast of ~215K tests
implies each rep must only convert ~15% (2.5 docs/month) of their ~200 targeted docs with
minimal contribution from larger instit